Latest from Florida Society of Clinical Oncology

Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.

Reshma L. Mahtani, DO, discusses the use of adjuvant endocrine therapy in premenopausal breast cancers, specifically the use of ovarian function suppression and GnRH agonists. 

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the updated data from the TEXT and SOFT clinical trials in premenopausal women with hormone-receptor positive (HR+) breast cancer.

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

Plasma- and urine-based assays designed to detect actionable mutations in patients with non–small cell lung cancer are changing the face of treatment for these patients.